证券代码：688566 证券简称：吉贝尔 江苏吉贝尔药业股份有限公司 投资者关系活动记录表 编号：2022-003 | --- | --- | --- | --- | --- | --- | |---------------------------|------------------------------------------------------|------------------------------------------------------------|------------------------|-------|----------| | | | | | | | | | □特定对象调研 □分析师会议 | | | | | | 投资者关系活 | □媒体采访 □√业绩说明会 | | | | | | 动类别 | □新闻发布会 □路演活动 | | | | | | | □现场参观 | | | | | | | □其他（请文字说明其他活动内容） | | | | | | 参与单位名称 及人员姓名 | 参与了本次业绩说明会的线上投资者 | | | | | | 时 间 | 2022 年 6 月 8 日 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥169,358,593.98, representing a 45.97% increase compared to the same period last year[5] - The net profit attributable to shareholders for Q3 2022 was ¥37,145,036.54, reflecting an 80.32% increase year-over-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥37,124,049.42, showing a significant increase of 112.45% compared to the previous year[5] - Basic and diluted earnings per share for Q3 2022 were both ¥0.20, an increase of 81.82% from the same period last year[6] - Total operating revenue for the first three quarters of 2022 reached CNY 426,569,744.86, an increase of 16.3% compared to CNY 366,826,002.01 in the same period of 2021[22] - Net profit for the third quarter of 2022 was CNY 78,942,288.10, representing a 4.0% increase from CNY 75,820,535.26 in the same quarter of 2021[23] - Basic and diluted earnings per share for the third quarter of 2022 were both CNY 0.42, compared to CNY 0.41 in the same quarter of 2021[24] Research and Development - The total R&D investment for Q3 2022 was ¥12,648,235.91, which is an 85.05% increase year-over-year[6] - R&D investment accounted for 7.47% of operating revenue in Q3 2022, up by 1.58 percentage points compared to the previous year[6] - Research and development expenses for new drugs increased by 75.68% year-on-year, totaling RMB 41,833,870.00[15] - Research and development expenses for the first three quarters of 2022 totaled CNY 41,833,870.00, significantly higher than CNY 23,813,200.62 in the same period of 2021, indicating a focus on innovation[22] - The company is advancing the development of new drugs JJH201501 and JJH201601[15] Assets and Liabilities - The total assets at the end of Q3 2022 were ¥1,883,772,433.02, a 3.58% increase from the end of the previous year[6] - Total assets as of September 30, 2022, amounted to RMB 1,883,772,433.02, compared to RMB 1,818,686,866.85 at the end of 2021[19] - Total liabilities as of the end of the third quarter of 2022 amounted to CNY 269,935,507.78, an increase from CNY 210,396,612.27 at the end of the previous year[21] - The equity attributable to shareholders at the end of Q3 2022 was ¥1,607,846,151.63, reflecting a slight increase of 0.37% from the previous year[6] - Total equity attributable to shareholders of the parent company was CNY 1,607,846,151.63, a slight increase from CNY 1,601,985,101.69 in the previous year[21] Cash Flow - The cash flow from operating activities for the year-to-date was ¥103,504,097.97, representing a 4.42% increase[6] - Net cash flow from operating activities was $103,504,097.97, an increase from $99,120,817.12 in the previous year, reflecting a growth of approximately 3.8%[26] - Cash inflow from investment activities totaled $1,117,618,312.08, down from $1,387,683,406.62, indicating a decrease of about 19.5% year-over-year[27] - Total cash and cash equivalents at the end of the period stood at $760,789,488.56, compared to $460,138,487.63 at the end of the same quarter last year, representing an increase of approximately 65.2%[27] - The net increase in cash and cash equivalents for the period was -$253,920,254.49, compared to -$826,895,200.08 in the same quarter last year, showing a significant improvement[27] Shareholder Information - The total number of common shareholders at the end of the reporting period is 8,038[13] - The largest shareholder, Zhenjiang Zhongtian Investment Consulting Co., Ltd., holds 54,400,000 shares, accounting for 29.10% of total shares[13] Legal and Other Matters - The company is currently involved in a legal dispute with Hubei Jiuzhoutong and has filed a counterclaim[16] - The company has implemented a stock incentive plan, granting 7.33 million restricted shares at a price of RMB 12.30 per share[15] - The company’s inventory increased to RMB 33,425,671.52 from RMB 31,825,596.70 year-on-year[19] - The company’s long-term equity investments decreased to RMB 52,045,854.00 from RMB 56,625,042.03[19] - The company reported a decrease in unallocated profits to CNY 301,650,497.89 from CNY 320,147,417.75 in the same period last year[21] - The company experienced a significant increase in other payables, which rose to CNY 76,132,821.76 from CNY 20,278,559.67 in the previous year[21]

Financial Performance - The company's operating revenue for the first half of 2022 was RMB 257,211,150.88, representing a 2.56% increase compared to RMB 250,803,104.55 in the same period last year[19]. - The net profit attributable to shareholders decreased by 24.33% to RMB 42,111,630.84 from RMB 55,649,582.17 year-on-year[19]. - The net profit after deducting non-recurring gains and losses fell by 34.84% to RMB 30,866,460.74 compared to RMB 47,368,235.14 in the previous year[19]. - The net cash flow from operating activities increased by 18.76% to RMB 66,217,847.68 from RMB 55,756,491.97 in the same period last year[19]. - The company's total assets as of June 30, 2022, were RMB 1,838,075,765.52, a 1.07% increase from RMB 1,818,686,866.85 at the end of the previous year[19]. - The net assets attributable to shareholders increased by 0.51% to RMB 1,610,104,975.76 from RMB 1,601,985,101.69 at the end of the previous year[19]. - Basic earnings per share decreased by 23.33% to RMB 0.23 from RMB 0.30 in the same period last year[21]. - The company reported a total revenue of 97,325.00 million RMB for the first half of 2022, with a net profit of 2,801.44 million RMB, representing a significant increase of 17,149.90 million RMB compared to the previous year[88]. Research and Development - The R&D investment accounted for 11.35% of operating revenue, an increase of 4.58 percentage points from 6.77% in the previous year[21]. - The company has increased its R&D investment significantly, with a total R&D expenditure of ¥29,185,634.09, representing a 71.90% increase compared to the previous year[77]. - The company is actively developing new drugs, including JJH201501 for depression, JJH201601 for cancer, and JJH201701 for gastric acid-related issues, among others, enhancing its product pipeline[93]. - The company has established a comprehensive drug research and development system, focusing on patient needs and clinical value, supported by a professional R&D team[53]. - The company is focusing on liposome drug delivery technology, which enhances drug targeting and stability[74]. - The company has developed several new drugs, including JJH201501, an antidepressant currently in Phase IIb clinical trials, showing improved pharmacokinetics and efficacy[43]. - The company is also developing JJH201601, a novel anti-tumor drug, utilizing liposome technology and preparing for clinical application submission[44]. - The company has received recognition as a provincial engineering technology research center with excellent performance in Jiangsu Province[75]. Market Position and Products - The company specializes in drug research and development across multiple therapeutic areas, including treatments for cancer and depression[25]. - The company's main products include tablets, capsules, and eye drops, with a focus on innovative drug development[28]. - The company’s product, Likujun tablets, is recognized for its efficacy in treating leukopenia and has been included in the National Basic Medical Insurance Directory[31]. - The company holds a unique position as the only domestic and international producer of Likujun raw materials and tablets, supported by patented technology[31]. - The company has launched the first compound antihypertensive drug, Nigunol Tablets, which is included in the National Basic Medical Insurance Directory (2021) and recommended in multiple hypertension treatment guidelines[33]. - The company is the sole manufacturer of Nigunol Tablets, with no generic versions available in the market, ensuring a unique market position[33]. - The company’s main product, Likujun tablets, holds a leading market share in oral leukocyte-increasing drugs, effectively treating leukopenia and thrombocytopenia[61]. - The company is increasing marketing efforts for its antihypertensive drug, Nigulol tablets, which uniquely lowers both blood pressure and heart rate, aiming for stable revenue growth[61]. Corporate Governance and Compliance - The report emphasizes that the financial report is guaranteed to be true, accurate, and complete by the responsible personnel[5]. - The board of directors has confirmed that all members attended the meeting, ensuring accountability[3]. - The company has not disclosed any special arrangements for corporate governance[8]. - The company has established a dedicated department for the operation and maintenance of wastewater treatment and air pollution control facilities, ensuring normal operation without major environmental issues[152]. - The company has recognized key technical personnel in drug research and development, including project leaders and main members of research institutes[145]. - The company has a valid wastewater discharge permit obtained in May 2021, valid for five years, ensuring compliance with environmental regulations[153]. - The company has implemented strict GMP standards in its production processes, ensuring product quality and compliance with pharmaceutical standards[100]. - The company has successfully maintained a record of zero quality and safety incidents during the reporting period[103]. Risks and Challenges - The decrease in net profit was primarily due to increased investment in new drug research and development and the stock-based compensation expenses related to the 2021 restricted stock incentive plan[21]. - The company faces risks related to the inability to obtain clinical trial approvals for its innovative drugs currently in preclinical research, with only JJH201501 having entered clinical trials[116]. - The company’s revenue heavily relies on the product Likujun tablets, which poses a risk if competition increases or market conditions change[118]. - The company is exposed to potential price reductions due to national drug procurement policies, which could significantly impact revenue and profitability[125]. - The company benefits from a reduced corporate income tax rate of 15% as a high-tech enterprise, but risks losing this status could adversely affect financial performance[126]. Environmental Responsibility - The company’s emissions of non-methane total hydrocarbons and nitrogen oxides are within the acceptable limits, demonstrating compliance with environmental standards[151]. - The company has made commitments regarding share lock-up periods, ensuring no share transfers for a specified duration post-IPO[161]. - The company is committed to social responsibility by promoting technological innovation and energy conservation, with all waste emissions consistently meeting regulatory standards[157]. - The company has a complete set of environmental protection documents, including administrative permits and emergency response plans, ensuring compliance with environmental laws and regulations[157]. - The company has implemented an environmental self-monitoring plan, ensuring that all pollutant indicators meet discharge standards as verified by a qualified third-party testing agency[155]. Shareholder Commitments - The company commits to increasing R&D investment and developing new products to meet customer demands[187]. - The company aims to enhance operational efficiency and profitability through improved management and internal controls[187]. - The controlling shareholder and actual controller commit to not interfering with the company's management activities[187]. - The company will publicly explain any failure to fulfill commitments and apologize to shareholders and investors[195]. - The company will bear full responsibility for any compensation payments resulting from legal disputes[19].

Financial Performance - The company's operating revenue for Q1 2022 was ¥138,822,101.80, representing a year-on-year increase of 15.61%[3] - The net profit attributable to shareholders for the same period was ¥28,584,367.50, reflecting a growth of 5.95% compared to the previous year[3] - The basic and diluted earnings per share were both ¥0.15, up by 7.14% year-on-year[3] - The company achieved operating revenue of RMB 138.82 million, representing a year-on-year growth of 15.61%[10] - The net profit attributable to shareholders was RMB 28.58 million, with a year-on-year increase of 5.95%[10] - The company's total comprehensive income for Q1 2022 was CNY 28,472,006.74, up from CNY 26,763,907.49 in Q1 2021[17] - The net profit for Q1 2022 reached CNY 28,472,006.74, representing a 6.4% increase from CNY 26,763,907.49 in Q1 2021[16] - The net profit for Q1 2022 was CNY 29,956,319.22, representing a growth of 14.67% from CNY 26,178,742.13 in Q1 2021[24] Cash Flow - The net cash flow from operating activities decreased by 7.07% to ¥17,129,889.13[3] - In Q1 2022, the company's net cash flow from operating activities was ¥21,049,508.91, a significant improvement compared to a net outflow of ¥6,263,744.38 in Q1 2021[26] - The company reported a decrease in cash flow from financing activities, resulting in a net cash decrease of CNY 508,134,903.65 for Q1 2022[19] - The company incurred cash payments for operating activities totaling ¥122,144,783.82 in Q1 2022, down from ¥159,105,892.23 in Q1 2021, a decrease of about 23.2%[26] - The company reported a total cash outflow from investing activities of ¥746,393,802.84 in Q1 2022, compared to ¥1,106,788,634.35 in the same period of 2021, indicating a reduction of about 32.5%[27] - The net cash flow from investment activities for Q1 2022 was -CNY 525,264,792.78, compared to -CNY 1,116,788,634.35 in the same period last year[19] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,829,821,119.93, showing a slight increase of 0.61% from the end of the previous year[4] - As of March 31, 2022, total assets amounted to RMB 1.83 billion, slightly up from RMB 1.82 billion at the end of 2021[12] - Current assets totaled RMB 1.37 billion, a decrease from RMB 1.41 billion at the end of 2021[12] - The total liabilities decreased to RMB 187.65 million from RMB 210.40 million at the end of 2021[13] - The total liabilities as of March 31, 2022, were CNY 197,714,362.68, a decrease from CNY 214,190,743.20 at the end of 2021[23] - The company's total equity as of March 31, 2022, was CNY 1,623,621,540.65, up from CNY 1,588,253,117.54 at the end of 2021[24] Research and Development - Research and development expenses totaled ¥7,028,935.99, accounting for 5.06% of operating revenue, which is an increase of 0.51 percentage points year-on-year[4] - Research and development expenses for Q1 2022 totaled CNY 7,028,935.99, an increase of 28.9% from CNY 5,463,969.51 in Q1 2021[15] - The company recognized share-based payment expenses of RMB 5.41 million during the reporting period[10] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 8,893[8] - The largest shareholder, Zhenjiang Zhongtian Investment Consulting Co., Ltd., held 29.10% of the shares, totaling 54,400,000 shares[8] Other Financial Information - The company reported a government subsidy of ¥526,800.34 included in non-operating income[5] - The company experienced a foreign exchange loss of CNY 289,980.84 in Q1 2022, compared to a gain of CNY 641,176.23 in Q1 2021[16] - The company reported a decrease in tax expenses to CNY 4,044,601.59 from CNY 4,267,060.80 in Q1 2021[16] - The company’s sales expenses for Q1 2022 were CNY 70,370,702.30, an increase of 12.93% compared to CNY 62,438,781.15 in Q1 2021[24]

Financial Performance - The company's operating revenue for 2021 was approximately ¥509.69 million, a decrease of 9.94% compared to ¥565.97 million in 2020[23]. - The net profit attributable to shareholders for 2021 was approximately ¥114.90 million, down 11.42% from ¥129.72 million in 2020[23]. - The net profit after deducting non-recurring gains and losses was approximately ¥93.18 million, a decrease of 18.34% compared to ¥114.10 million in 2020[23]. - Basic earnings per share decreased by 20.78% to 0.61 yuan per share compared to 2020[25]. - The weighted average return on equity fell by 4.40 percentage points to 7.22% in 2021[25]. - The gross profit margin for the pharmaceutical manufacturing segment was 87.81%, a decrease of 0.87 percentage points compared to the previous year[145]. - Sales of the main product, Likujun tablets, generated revenue of ¥378,463,930.34, a decline of 17.07% year-on-year[145]. - The company reported a total revenue of 97,325,000 RMB, with a net profit of 2,643,020 RMB for the year 2021[112]. Dividends and Shareholder Returns - The company plans to distribute a cash dividend of RMB 2.40 per 10 shares, totaling RMB 44,865,984.00 (including tax) for the 2021 fiscal year[7]. - The total cash dividends for 2021 will amount to RMB 89,731,968.00 (including tax), representing 78.09% of the net profit attributable to shareholders[8]. Audit and Governance - The company has received a standard unqualified audit report from the accounting firm Xin Yong Zhong He[6]. - The board of directors has confirmed the authenticity, accuracy, and completeness of the annual report[4]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[10]. - The company has not reported any special arrangements for corporate governance[9]. - The company has not experienced any violations of decision-making procedures regarding external guarantees[10]. Research and Development - The total R&D expenditure for the year was approximately ¥29.28 million, a decrease of 12.71% compared to the previous year[107]. - R&D expenditure accounted for 5.75% of the company's total revenue, down from 5.93% in the previous year, representing a decrease of 0.18 percentage points[107]. - The company is developing several new drugs, including JJH201501 for depression and JJH201601 for cancer treatment, among others[117]. - The company has a pipeline of innovative drugs, including Lifitegrast derivatives for dry eye treatment and JBE-01 for anesthesia and analgesia, currently in preclinical stages[173]. - The company has not canceled any major R&D projects or failed to obtain approvals for any products during the reporting period[174]. Market and Industry Trends - The global pharmaceutical market reached $1,298.8 billion in 2020, with a projected CAGR of 5.7% to reach $1,711.4 billion by 2025[76]. - The Chinese pharmaceutical market is expected to grow at a CAGR of 9.6% over the next five years, reaching ¥2,991.1 billion by 2030[79]. - The pharmaceutical industry is expected to benefit from multiple factors, including an aging population and health consumption upgrades, leading to promising development opportunities in the future[82]. Product Development and Innovation - The company is actively advancing new drug research, with several candidates in various stages of clinical trials, including JJH201501 for depression, which is currently in Phase IIb trials[45]. - The company has successfully expanded the sales of its product, Nicergoline tablets, across 26 provinces in China, contributing to stable revenue growth[42]. - The company has developed a new antidepressant drug JJH201501, which is currently in the IIb clinical trial phase after completing Phase I trials and has received patent authorization in China, the US, and Europe[171]. - The oncology drug JJH201601 is preparing to submit for clinical application after completing pharmacological and toxicological studies[172]. Risks and Challenges - The company has detailed various risks faced in its production and operation processes in the report[5]. - The company faces risks related to the potential for its main products to be included in centralized procurement lists, which could lead to significant price reductions and impact profitability[139]. - The company is exposed to risks from potential breakthroughs in the treatment areas of its pipeline drugs, which could lead to competitive pressures[128]. Marketing and Sales Strategy - The company has established a comprehensive marketing network across all provinces in China, enhancing the promotion of its key products[43]. - The marketing network covers over 20,000 hospitals and medical institutions nationwide, including 65 of the top 100 chain pharmacies[120]. - The company intends to increase the market promotion efforts for existing products like Likujun tablets and Nifedipine tablets to capture untapped market segments[200]. Financial Position and Assets - As of the end of 2021, the net assets attributable to shareholders were approximately ¥1.60 billion, an increase of 2.07% from ¥1.57 billion at the end of 2020[23]. - Total assets reached 1.8186869 billion yuan, with net assets attributable to shareholders at 1.6019851 billion yuan by the end of 2021[38]. - Accounts receivable and notes receivable totaled CNY 146.60 million, representing 10.43% of current assets and 28.76% of operating revenue, indicating potential credit risk as revenue grows[137].

2021 年第三季度报告 证券代码：688566 证券简称：吉贝尔 江苏吉贝尔药业股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上 年同期增减变 | 年初至报告期末 | 年初至报告 期末比上年 | | --- | --- | --- | --- | --- | | | | 动幅度(%) | | 同期增减变 | | | | | | 动幅度(%) | | 营业收入 | 116,022,897.46 | -27.44 | 366,826,002.01 | -8.97 ...

Financial Performance - The company's operating revenue for the first half of 2021 was ¥250,803,104.55, representing a 3.18% increase compared to ¥243,071,635.30 in the same period last year [21]. - The net profit attributable to shareholders for the first half of 2021 was ¥55,649,582.17, a 22.31% increase from ¥45,499,584.95 in the previous year [21]. - The net cash flow from operating activities increased by 29.31% to ¥55,756,491.97, compared to ¥43,117,505.78 in the same period last year [21]. - The company's total assets as of June 30, 2021, were ¥1,740,365,664.06, a decrease of 0.39% from ¥1,747,264,306.69 at the end of the previous year [21]. - The net assets attributable to shareholders increased by 0.69% to ¥1,580,266,474.17 from ¥1,569,482,876.00 at the end of the previous year [21]. - Basic earnings per share for the first half of 2021 were ¥0.30, a decrease of 3.23% from ¥0.31 in the same period last year [22]. - The company reported a total revenue of 82,325.00 million RMB for the first half of 2021, with a net profit of 1,576.53 million RMB, representing a significant increase compared to the previous period [64]. Research and Development - The R&D expenditure as a percentage of operating revenue was 6.77%, slightly up from 6.73% in the previous year [22]. - Total R&D investment for the reporting period was approximately ¥16.98 million, representing a 3.76% increase from the previous period, with R&D expenses accounting for 6.77% of total revenue [59]. - The company is actively developing innovative drugs targeting depression, tumors, and gastrointestinal diseases, among others [29]. - The company is conducting Phase II clinical trials for the new antidepressant JJH201501, which has shown significant improvement in drug retention time and blood concentration [37]. - The anti-tumor drug JJH201601 has demonstrated a tumor inhibition rate exceeding 99% in mouse models, with no recurrence observed during the observation period [38]. - The company has established a comprehensive drug research and development system, including five functional departments, covering all aspects from compound screening to industrialization [44]. - The company has established collaborations with various research institutions and CROs to enhance its R&D capabilities and ensure the smooth progress of new product development [74]. Market and Product Development - The Chinese pharmaceutical market is projected to reach 2.1 trillion yuan by 2023, indicating significant growth opportunities for the industry [28]. - The company's leading product, Likujun tablets, is a representative oral drug for leukocyte enhancement, widely used in thousands of hospitals across China [31]. - The company is focusing on the hypertension market, with the expectation that the anti-hypertensive drug market in China will exceed 100 billion yuan by 2022, and is promoting its product, Nigulol tablets, in this segment [80]. - The company has a diverse product range, including chemical raw materials and formulations, catering to various therapeutic areas such as hypertension and immune enhancement [69]. - The company is actively promoting the sales of its key product, Likujun tablets, which is in a growth phase with significant market potential and has initiated various promotional activities [79]. Corporate Governance and Compliance - The report indicates that the company has not faced any non-operating fund occupation by controlling shareholders or related parties [7]. - The board of directors has confirmed that all members attended the board meeting, ensuring the report's authenticity and completeness [5]. - There are no special arrangements for corporate governance or significant matters applicable to the company [6]. - The company has not violated decision-making procedures for external guarantees [7]. - The report is unaudited, and the responsible persons have declared the financial report's accuracy and completeness [5]. - The company has committed to maintaining transparency and accuracy in its financial disclosures to protect investor interests and will be liable for any misleading information [157]. Environmental Responsibility - The company is classified as a key pollutant discharge unit, with wastewater emissions meeting regulatory standards [121]. - The maximum concentration of ammonia nitrogen in wastewater discharge was 0.823 mg/L, well below the limit of 35 mg/L [121]. - The company has established a dedicated department for the operation and maintenance of pollution control facilities [122]. - The company has developed an emergency response plan for potential environmental incidents, filed with the local environmental protection bureau [125]. - The company is committed to sustainable development by minimizing pollutant emissions from new projects [124]. Shareholder Commitments and Stock Management - The company has committed to a share lock-up period of 36 months following its IPO, during which it will not transfer or manage its shares [131]. - The actual controller and chairman, Geng Zhongyi, has also pledged not to transfer his shares for 36 months post-IPO, with a similar lock-up extension clause if share prices fall below the IPO price [133]. - The company has a structured plan for managing potential conflicts of interest and related party transactions [130]. - The company will not reduce its shareholding if it is subject to public reprimand by the stock exchange for less than three months [137]. - The company will implement stock price stabilization measures if the stock price falls below the audited net asset value per share for 20 consecutive trading days [148]. - The company plans to repurchase shares as part of its stock price stabilization strategy, with a total repurchase amount not exceeding 10% of the total issued shares [149].

Financial Performance - Operating revenue for the current period was CNY 120,075,236.69, an increase of 3.04% year-on-year[6] - Net profit attributable to shareholders was CNY 26,979,212.29, reflecting a growth of 7.48% compared to the same period last year[6] - Basic and diluted earnings per share were both CNY 0.14, a decrease of 22.22% compared to the previous year[6] - The company's total revenue for Q1 2021 was CNY 119,593,936.96, representing an increase of 2.0% compared to CNY 116,278,146.76 in Q1 2020[30] - The net profit for Q1 2021 was CNY 26,178,742.13, up from CNY 25,460,349.57 in Q1 2020, reflecting a growth of 2.8%[31] - The operating profit for Q1 2021 was CNY 30,433,673.17, compared to CNY 29,601,074.92 in Q1 2020, indicating an increase of 2.8%[30] - The total profit for Q1 2021 was CNY 30,060,142.41, slightly higher than CNY 29,558,464.83 in Q1 2020, reflecting a growth of 1.7%[30] Cash Flow - The cash flow from operating activities was CNY 18,432,797.31, down 16.81% from the previous year[6] - Cash inflow from operating activities in Q1 2021 was CNY 154,542,686.92, compared to CNY 133,129,419.40 in Q1 2020, marking an increase of 16.1%[33] - The net cash flow from operating activities for Q1 2021 was -6,263,744.38 RMB, a significant decrease compared to 21,439,752.90 RMB in Q1 2020[35] - Total cash outflow from operating activities amounted to 159,105,892.23 RMB, up from 110,160,063.91 RMB in the previous year, indicating a 44.4% increase[35] - The company reported a net cash outflow from investing activities of -1,106,788,634.35 RMB, worsening from -52,323,865.94 RMB in the same period last year[36] - Cash inflow from other investment activities was 20,000,000.00 RMB, which was not present in the previous year[35] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,741,341,416.29, a decrease of 0.34% compared to the end of the previous year[6] - Total liabilities decreased to ¥51,215,822.65 from ¥84,008,017.67[20] - The total assets as of March 31, 2021, amounted to CNY 1,720,033,451.24, a decrease from CNY 1,750,306,868.45 at the end of 2020[23] - Total liabilities as of March 31, 2021, were CNY 141,034,117.34, down from CNY 197,486,276.68 at the end of 2020, showing a reduction of 28.6%[24] - Cash and cash equivalents decreased by 85.32% to ¥189,007,850.67 from ¥1,287,363,687.71 due to temporary idle funds being used to purchase structured deposits[16] - Cash and cash equivalents decreased to CNY 167,402,676.77 from CNY 1,280,455,055.50 at the end of 2020, indicating a significant decline[22] Shareholder Information - The total number of shareholders at the end of the reporting period was 10,476[11] - The top shareholder, Zhenjiang Zhongtian Investment Consulting Co., Ltd., held 54,400,000 shares, accounting for 29.10% of total shares[11] Research and Development - The R&D investment accounted for 4.55% of operating revenue, an increase of 0.36 percentage points year-on-year[6] - Research and development expenses for Q1 2021 amounted to CNY 5,463,969.51, which is a rise from CNY 4,888,224.28 in Q1 2020, showing an increase of 11.7%[30] Other Financial Metrics - The company reported non-recurring gains and losses totaling CNY 1,167,831.82[9] - Other income increased by 175.50% to ¥1,894,670.48 from ¥687,710.12 due to an increase in government subsidies received during the reporting period[17] - Investment income decreased by 100% to ¥0.00 from ¥8,141.64 as no financial management income was received during the reporting period[17] - Employee compensation payable decreased by 68.58% to ¥6,274,095.83 from ¥19,969,419.59 primarily due to the payment of last year's year-end bonuses[16] - Tax payable decreased by 55.24% to ¥7,385,116.79 from ¥16,501,034.29 mainly due to a reduction in payable VAT and income tax compared to the end of the previous year[16] - Other payables decreased by 30.60% to ¥14,290,487.04 from ¥20,592,699.35 due to the payment of last year's expenses[16]

Dividend Distribution - The company plans to distribute a cash dividend of RMB 2.40 per 10 shares, totaling RMB 44,865,984.00, which represents 69.17% of the net profit attributable to shareholders for the year[6]. - The total share capital of the company is 186,941,600 shares, and the proposed dividend distribution is subject to approval at the shareholders' meeting[5]. - The company distributed cash dividends of RMB 2.40 per 10 shares, totaling RMB 44,865,984.00 (including tax) on October 19, 2020[164]. - In 2020, the cash dividend accounted for 69.17% of the net profit attributable to ordinary shareholders, amounting to RMB 89,731,968.00[166]. - The company plans to maintain a minimum cash dividend ratio of 80% for mature stages without significant capital expenditure, and 40% if there are major expenditures[162]. - The board of directors is required to consider the timing, conditions, and minimum ratio for cash dividends, ensuring independent directors fulfill their responsibilities[163]. - The company has a policy to prioritize cash dividends over stock dividends when conditions allow[162]. - The cash dividend policy must comply with the company's articles of association and shareholder resolutions[163]. - The company has not proposed a cash profit distribution plan during the reporting period despite having positive distributable profits[167]. - The company will actively communicate with minority shareholders regarding cash dividend proposals to ensure their opinions are considered[163]. Financial Performance - The company's operating revenue for 2020 was ¥565,973,500.28, representing a 4.32% increase compared to ¥542,519,478.27 in 2019[21]. - The net profit attributable to shareholders for 2020 was ¥129,717,585.18, which is a 14.88% increase from ¥112,914,539.88 in 2019[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥114,098,834.10, up by 3.72% from ¥110,007,550.42 in 2019[21]. - The net cash flow from operating activities for 2020 was ¥117,363,183.77, reflecting a 1.66% increase from ¥115,448,696.06 in 2019[21]. - The total assets of the company reached CNY 1,747.2643 million, with net assets of CNY 1,576.3422 million by the end of 2020[84]. - The gross profit margin for the pharmaceutical manufacturing segment was 88.89%, an increase of 0.67 percentage points compared to the previous year[111]. - The revenue from Licorice Tablets was ¥443,060,314.62, with a gross margin of 93.27%, showing a 9.11% increase in revenue compared to the previous year[111]. - The company reported a decrease in financial expenses due to increased interest income from raised funds[125]. - The company achieved a systematic secondary development of the active pharmaceutical ingredient (API) for Licorice Tablets, improving the raw material content to over 99%[53]. Research and Development - The total R&D investment for the year was approximately ¥33.55 million, representing a 7.67% increase from the previous year, with R&D expenses accounting for 5.93% of total revenue[62]. - The company is actively pursuing various R&D projects, including clinical studies for the antidepressant JJH201501, supported by local government funding[60]. - The company has invested a total of RMB 11,705 million in research and development, with a current period investment of RMB 3,185 million[69]. - The number of R&D personnel has increased to 115, representing 12.60% of the total workforce, up from 11.62% in the previous period[71]. - The company is focusing on innovative drug development, supported by national policies that encourage pharmaceutical innovation and expedite drug approval processes[50]. - The company has developed a unique compound antihypertensive drug, Nigunol Tablets, which is included in the National Basic Medical Insurance Directory (2020) and recommended in multiple hypertension treatment guidelines[32]. - The company is advancing its new antidepressant JJH201501, which has shown significant efficacy and lower side effects compared to first-line treatments, currently in Phase II clinical trials[48]. - The new anti-tumor drug JJH201601 has demonstrated over 99% tumor suppression in preclinical studies, indicating strong potential for future development[48]. - The company has multiple new drugs in development, including JJH201501 (antidepressant) and JJH201601 (anticancer), among others[79]. Market and Competition - The global pharmaceutical market is projected to grow from $1.13 trillion in 2016 to $1.5 trillion in 2021, with a compound annual growth rate (CAGR) of 4% to 7% over five years[44]. - China's pharmaceutical market is expected to reach ¥2.1 trillion by 2023, outpacing global market growth[44]. - The company faces risks related to the potential for major product imitation or substitution, particularly concerning its key product, Likujun[94]. - There are risks associated with the clinical trial approval process for new drugs, which may not meet expectations or regulatory requirements[95][97]. - The company faces risks from intensified market competition, particularly from domestic leaders like Heng Rui Medicine and Yangtze River Pharmaceutical[102]. - There is a potential risk of price reductions due to national drug procurement policies, which could significantly impact revenue and profitability[105]. Corporate Governance and Compliance - The company has received a standard unqualified audit report from the accounting firm Xin Yong Zhong He[7]. - There are no non-operating fund occupations by controlling shareholders or related parties reported[8]. - The company does not have any special arrangements for corporate governance or significant matters that require disclosure[8]. - The company has not violated decision-making procedures for external guarantees[8]. - The company has not faced any issues with a majority of directors being unable to ensure the authenticity and completeness of the annual report[8]. - The company has strengthened its internal control systems and governance structures to enhance operational efficiency and risk management[91]. - The company commits to strictly adhere to relevant laws and regulations, ensuring fair decision-making in related party transactions[197]. - The company guarantees that it will not use related party relationships to illegally occupy company funds or assets[198]. Production and Quality Control - The company employs a "planned production" model, ensuring that production meets market demand while maintaining safety stock levels[40]. - All production processes comply with GMP certification, ensuring that products meet quality standards before reaching the market[40]. - The procurement strategy involves rigorous supplier evaluation and quality control to ensure the safety and quality of raw materials[39]. - The company has maintained stable production operations during the COVID-19 pandemic, effectively minimizing its impact on production and sales[85]. Shareholder Commitments and Restrictions - The controlling shareholder, Zhongtian Investment, committed to not transferring or managing shares for 36 months post-IPO, with a minimum selling price not lower than the issue price after the lock-up period[169]. - The actual controller and chairman, Geng Zhongyi, also pledged not to transfer shares for 36 months post-IPO, with similar conditions regarding the selling price and lock-up extensions[172]. - The company commits to not transferring or managing shares held prior to the IPO for 12 months post-listing, with an automatic extension of the lock-up period by at least 6 months if the stock price falls below the IPO price for 20 consecutive trading days[175]. - The company will not reduce shareholdings during investigations or legal proceedings related to securities violations[170]. - Any violations of these commitments will result in the company bearing all legal responsibilities[172]. - The company will ensure compliance with all relevant laws and regulations during the share repurchase process[185].

Financial Performance - Net profit attributable to shareholders increased by 6.33% year-over-year, amounting to CNY 78,821,896.76[6] - The company reported a significant increase in investment income, which rose by 929.25% to 2,731,196.59 RMB, primarily due to increased interest income from structured deposits[16] - The company reported a net cash flow from operating activities of 86,452,497.93 RMB, a 43.82% increase compared to the same period in 2019, mainly due to government subsidies related to assets[16] - The company’s net profit for the first three quarters of 2020 reached ¥78,099,968.15, compared to ¥75,416,494.97 in the same period of 2019, showing a growth of about 3.4%[38] - The total profit for Q3 2020 was ¥37,770,191.09, compared to ¥29,793,754.80 in Q3 2019, indicating a year-over-year increase of approximately 26.5%[37] Assets and Liabilities - Total assets increased by 189.76% year-over-year, reaching CNY 1,725,875,235.31[6] - Total liabilities reached CNY 200,443,944.90, up from CNY 125,158,317.20, showing an increase of about 60%[23] - The total assets as of Q3 2020 amounted to ¥1,730,301,751.55, compared to ¥592,720,170.48 in the previous year, showing a significant increase[28] - Total liabilities for Q3 2020 were ¥228,106,395.36, up from ¥144,647,259.63 in Q3 2019, which is an increase of about 57.7%[28] - The company's long-term deferred expenses rose by 104.53% to 4,580,040.69 RMB, driven by increased costs for technical renovations and drug re-registration fees[15] Shareholder Information - Net assets attributable to shareholders rose by 227.46% compared to the previous year, totaling CNY 1,518,587,187.58[6] - The total number of shareholders at the end of the reporting period was 12,444[11] - Shareholders' equity rose to CNY 1,525,431,290.41 from CNY 470,462,545.73, representing a growth of approximately 224%[24] - The total equity attributable to shareholders was ¥463,742,813.63[47] Revenue and Expenses - Operating income for the first nine months remained stable at CNY 402,963,858.69, showing a 0.00% change year-over-year[6] - Total operating revenue for Q3 2020 reached ¥159,892,223.39, an increase from ¥146,939,257.53 in Q3 2019, representing an increase of approximately 8.3%[31] - Total operating costs for Q3 2020 were ¥122,870,951.77, compared to ¥118,545,451.87 in Q3 2019, reflecting an increase of about 2.8%[31] - Research and development expenses accounted for 5.82% of operating income, up by 0.13 percentage points from the previous year[6] - Research and development expenses for Q3 2020 were ¥7,102,847.76, a decrease from ¥12,082,979.08 in Q3 2019, indicating a reduction of about 41.5%[32] Cash Flow - The net cash flow from operating activities for the third quarter of 2020 was CNY 86,452,497.93, up from CNY 60,112,002.08 in Q3 2019, representing a year-over-year increase of approximately 43%[40] - The company raised CNY 1,038,274,635.43 from financing activities in the first three quarters of 2020, with a net cash flow from financing activities of CNY 1,027,240,536.66, a significant improvement from negative cash flow in the previous year[43] - The ending cash and cash equivalents balance for the third quarter of 2020 was CNY 182,835,395.71, compared to CNY 116,546,566.95 at the end of Q3 2019, reflecting a year-over-year increase of approximately 56.7%[41] Changes in Financial Position - The weighted average return on equity decreased by 10.87 percentage points to 8.24%[6] - Basic earnings per share decreased by 7.55% to CNY 0.49[6] - The company has not indicated any significant changes in its profit forecast for the upcoming reporting period[18] - The company implemented a new revenue accounting standard starting January 1, 2020, affecting financial reporting[48]